<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00445744</url>
  </required_header>
  <id_info>
    <org_study_id>2130.00</org_study_id>
    <secondary_id>NCI-2010-00270</secondary_id>
    <secondary_id>P01HL036444</secondary_id>
    <nct_id>NCT00445744</nct_id>
  </id_info>
  <brief_title>Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome</brief_title>
  <official_title>Cyclophosphamide Followed by Intravenous Busulfan as Conditioning for Hematopoietic Cell Transplantation in Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is studying the side effects and how well giving cyclophosphamide and busulfan
      followed by donor stem cell transplant works in treating patients with myelofibrosis, acute
      myeloid leukemia, or myelodysplastic syndrome. Giving chemotherapy, such as cyclophosphamide
      and busulfan, before a donor stem cell transplant helps stops the growth of cancer cells. It
      also helps stop the patient's immune system from rejecting the donor's stem cells. The
      donated stem cells may replace the patient's immune cells and help destroy any remaining
      cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can
      also make an immune response against the body's normal cells. Giving tacrolimus and
      methotrexate after the transplant may stop this from happening
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To estimate the incidence of hepatotoxicity with a conditioning regimen of CY
      (cyclophosphamide)/tBU (busulfan) in patients receiving hematopoietic cell transplant (HCT).

      SECONDARY OBJECTIVES:

      I. To determine overall and non-relapse mortality at day +200 after HCT.

      II. To determine the peak bilirubin levels through day +20 after HCT.

      III. To determine the incidence of pulmonary toxicity in the form of idiopathic pulmonary
      syndrome (IPS).

      IV. To determine the rate of graft failure.

      V. To determine the time to engraftment.

      VI. To determine the rate of relapse.

      VII. To determine the incidence and severity of graft-versus-host disease (GVHD).

      VIII. To evaluate the pharmacokinetics/dynamics of BU and CY.

      X. To evaluate the pharmacogenomics of response, toxicity and pharmacokinetics of CY/tBU.

      OUTLINE:

      CONDITIONING REGIMEN: Patients receive cyclophosphamide intravenously (IV) on days -7 and -6
      and busulfan IV over 3 hours on days -5 to -2.

      TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplant on day 0.

      POST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive tacrolimus IV or orally (PO) twice daily
      on days -1 to 200 with taper on day 56 and methotrexate on days 1, 3, 6, and 11.

      After completion of study treatment, patients are followed periodically.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness of Cyclophosphamide/Busulfan Regimen in Reducing Regimen-related Liver Toxicity</measure>
    <time_frame>Up to day +20</time_frame>
    <description>Number of patients with regimen-related liver toxicity. Diagnoses will be made according to the established criteria initially proposed in 1984 by McDonald et al.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-relapse Mortality (NRM) (Patients With AML/MDS)</measure>
    <time_frame>Up to day 200</time_frame>
    <description>Cumulative incidence rate with death as a competing risk, assessed at day 100.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Adult Acute Myeloid Leukemia in Remission</condition>
  <condition>Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities</condition>
  <condition>Adult Acute Myeloid Leukemia With Del(5q)</condition>
  <condition>Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)</condition>
  <condition>Childhood Acute Myeloid Leukemia in Remission</condition>
  <condition>Childhood Myelodysplastic Syndromes</condition>
  <condition>de Novo Myelodysplastic Syndromes</condition>
  <condition>Essential Thrombocythemia</condition>
  <condition>Myelodysplastic Syndrome With Isolated Del(5q)</condition>
  <condition>Polycythemia Vera</condition>
  <condition>Previously Treated Myelodysplastic Syndromes</condition>
  <condition>Primary Myelofibrosis</condition>
  <condition>Recurrent Adult Acute Myeloid Leukemia</condition>
  <condition>Recurrent Childhood Acute Myeloid Leukemia</condition>
  <condition>Secondary Acute Myeloid Leukemia</condition>
  <condition>Secondary Myelodysplastic Syndromes</condition>
  <condition>Secondary Myelofibrosis</condition>
  <condition>Untreated Adult Acute Myeloid Leukemia</condition>
  <condition>Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies</condition>
  <arm_group>
    <arm_group_label>Treatment (cyclophosphamide, busulfan, transplant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CONDITIONING REGIMEN: Patients receive cyclophosphamide IV on days -7 and -6 and busulfan IV over 3 hours on days -5 to -2.
TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplant on day 0.
POST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive tacrolimus IV or PO twice daily on days -1 to 200 with taper on day 56 and methotrexate on days 1, 3, 6, and 11.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (cyclophosphamide, busulfan, transplant)</arm_group_label>
    <other_name>CPM</other_name>
    <other_name>CTX</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Endoxan</other_name>
    <other_name>Endoxana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (cyclophosphamide, busulfan, transplant)</arm_group_label>
    <other_name>BSF</other_name>
    <other_name>BU</other_name>
    <other_name>Misulfan</other_name>
    <other_name>Mitosan</other_name>
    <other_name>Myeloleukon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Treatment (cyclophosphamide, busulfan, transplant)</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (cyclophosphamide, busulfan, transplant)</arm_group_label>
    <other_name>amethopterin</other_name>
    <other_name>Folex</other_name>
    <other_name>methylaminopterin</other_name>
    <other_name>Mexate</other_name>
    <other_name>MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>cytogenetic analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (cyclophosphamide, busulfan, transplant)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (cyclophosphamide, busulfan, transplant)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (cyclophosphamide, busulfan, transplant)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacogenomic studies</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (cyclophosphamide, busulfan, transplant)</arm_group_label>
    <other_name>Pharmacogenomic Study</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>Undergo PBPC transplantation</description>
    <arm_group_label>Treatment (cyclophosphamide, busulfan, transplant)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSC transplantation</other_name>
    <other_name>peripheral blood progenitor cell transplantation</other_name>
    <other_name>transplantation, peripheral blood stem cell</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
    <description>Undergo allogeneic transplantation</description>
    <arm_group_label>Treatment (cyclophosphamide, busulfan, transplant)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Idiopathic myelofibrosis (CIMF)

          -  Myelofibrosis developing with polycythemia vera or essential thrombocythemia

          -  Acute myeloid leukemia with or without antecedent hematologic disorder, at any disease
             stage (complete remission, minimal residual disease, or relapsed leukemia)

          -  Myelodysplastic syndrome of any World Health Organization (WHO) or
             French-American-British (FAB) category, at any disease stage

          -  Less than 61 years of age if transplanted from an unrelated donor, or less than 66
             years of age if transplanted from a related donor

          -  Receiving unmanipulated peripheral blood stem cells from an human leukocyte antigen
             (HLA)-identical or 1-allele-mismatched related or unrelated donor, or receiving
             G-CSF-stimulated bone marrow if co-enrolled on Fred Hutchinson Cancer Research Center
             (FHCRC) protocol 2250

          -  With a Karnofsky Performance score of &gt; 70% at the time of pre-transplant evaluation

          -  Able to give informed consent (if &gt;= 18 years of age), or with a legal guardian
             capable of giving consent (if &lt; 18 years of age)

          -  DONOR: HLA-identical or 1-allele-mismatched related or unrelated donors (by high
             resolution typing)

          -  DONOR: Undergoing peripheral blood stem cell harvest or G-CSF-stimulated bone marrow
             harvest (bone marrow permitted only as part of FHCRC protocol 2250)

          -  DONOR: In good general health, with a Karnofsky performance score of &gt; 80%

          -  DONOR: Able to give informed consent (if &gt;= 18 years of age), or with a legal guardian
             able to give informed consent (if &lt; 18 years of age and donating for a related
             transplant)

        Exclusion Criteria:

          -  Without an HLA-identical or 1-allele-mismatched related or unrelated donor

          -  With human immunodeficiency virus (HIV) positivity or active infectious hepatitis

          -  Receiving a medication known to strongly inhibit enzymes in the CYP450 pathway, and
             which, in the judgment of the consenting provider, cannot be safely discontinued for
             the duration of conditioning

          -  Whose life expectancy is severely limited by diseases other than the hematologic
             disorder for which they are undergoing HCT (HCT-comorbidity index [CI] &gt; 3)

          -  Women who are pregnant or lactating

          -  With known hypersensitivity to BU or CY

          -  With hepatic dysfunction as evidenced by total bilirubin or AST &gt; 2x the upper limit
             of normal, or evidence of synthetic dysfunction or cirrhosis

          -  With impaired renal function, as evidenced by creatinine clearance &lt; 50% of expected,
             creatinine &gt; 2x the upper limit of normal, or dialysis dependence

          -  With impaired pulmonary function, as evidenced by pO2 &lt; 70 mm Hg and diffusing
             capacity of carbon monoxide (DLCO) &lt; 70% predicted or by pO2 &lt; 80 mm Hg and DLCO &lt;
             60%, or receiving continuous supplementary oxygen

          -  With impaired cardiac function, as evidenced by ejection fraction &lt; 35% or active
             coronary artery disease

          -  Unable to give informed consent

          -  DONOR: Deemed unable to undergo stem cell collection, for any reason

          -  DONOR: HIV-positive, or hepatitis B or C antigen-positive

          -  DONOR: Women with a positive pregnancy test

          -  DONOR: Unable to give informed consent (if &gt;= 18 years of age), or without a legal
             guardian able to give informed consent (if &lt;18 years of age)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Rezvani</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2007</study_first_submitted>
  <study_first_submitted_qc>March 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2007</study_first_posted>
  <results_first_submitted>April 5, 2017</results_first_submitted>
  <results_first_submitted_qc>December 1, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">January 2, 2018</results_first_posted>
  <last_update_submitted>December 1, 2017</last_update_submitted>
  <last_update_submitted_qc>December 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fred Hutchinson Cancer Research Center</investigator_affiliation>
    <investigator_full_name>Joachim Deeg</investigator_full_name>
    <investigator_title>Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Cyclophosphamide, Busulfan, Transplant)</title>
          <description>CONDITIONING REGIMEN: Patients receive cyclophosphamide IV on days -7 and -6 and busulfan IV over 3 hours on days -5 to -2.
TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplant on day 0.
POST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive tacrolimus IV or PO twice daily on days -1 to 200 with taper on day 56 and methotrexate on days 1, 3, 6, and 11.
cyclophosphamide: Given IV
busulfan: Given IV
tacrolimus: Given IV or PO
methotrexate: Given IV
cytogenetic analysis: Correlative studies
flow cytometry: Correlative studies
pharmacological study: Correlative studies
pharmacogenomic studies: Correlative studies
peripheral blood stem cell transplantation: Undergo PBPC transplantation
allogeneic hematopoietic stem cell transplantation: Undergo allogeneic transplantation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Cyclophosphamide, Busulfan, Transplant)</title>
          <description>CONDITIONING REGIMEN: Patients receive cyclophosphamide IV on days -7 and -6 and busulfan IV over 3 hours on days -5 to -2.
TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplant on day 0.
POST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive tacrolimus IV or PO twice daily on days -1 to 200 with taper on day 56 and methotrexate on days 1, 3, 6, and 11.
cyclophosphamide: Given IV
busulfan: Given IV
tacrolimus: Given IV or PO
methotrexate: Given IV
cytogenetic analysis: Correlative studies
flow cytometry: Correlative studies
pharmacological study: Correlative studies
pharmacogenomic studies: Correlative studies
peripheral blood stem cell transplantation: Undergo PBPC transplantation
allogeneic hematopoietic stem cell transplantation: Undergo allogeneic transplantation</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="51"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" lower_limit="30" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effectiveness of Cyclophosphamide/Busulfan Regimen in Reducing Regimen-related Liver Toxicity</title>
        <description>Number of patients with regimen-related liver toxicity. Diagnoses will be made according to the established criteria initially proposed in 1984 by McDonald et al.</description>
        <time_frame>Up to day +20</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Cyclophosphamide, Busulfan, Transplant)</title>
            <description>CONDITIONING REGIMEN: Patients receive cyclophosphamide IV on days -7 and -6 and busulfan IV over 3 hours on days -5 to -2.
TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplant on day 0.
POST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive tacrolimus IV or PO twice daily on days -1 to 200 with taper on day 56 and methotrexate on days 1, 3, 6, and 11.
cyclophosphamide: Given IV
busulfan: Given IV
tacrolimus: Given IV or PO
methotrexate: Given IV
cytogenetic analysis: Correlative studies
flow cytometry: Correlative studies
pharmacological study: Correlative studies
pharmacogenomic studies: Correlative studies
peripheral blood stem cell transplantation: Undergo PBPC transplantation
allogeneic hematopoietic stem cell transplantation: Undergo allogeneic transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Effectiveness of Cyclophosphamide/Busulfan Regimen in Reducing Regimen-related Liver Toxicity</title>
          <description>Number of patients with regimen-related liver toxicity. Diagnoses will be made according to the established criteria initially proposed in 1984 by McDonald et al.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Non-relapse Mortality (NRM) (Patients With AML/MDS)</title>
        <description>Cumulative incidence rate with death as a competing risk, assessed at day 100.</description>
        <time_frame>Up to day 200</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Cyclophosphamide, Busulfan, Transplant)</title>
            <description>CONDITIONING REGIMEN: Patients receive cyclophosphamide IV on days -7 and -6 and busulfan IV over 3 hours on days -5 to -2.
TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplant on day 0.
POST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive tacrolimus IV or PO twice daily on days -1 to 200 with taper on day 56 and methotrexate on days 1, 3, 6, and 11.
cyclophosphamide: Given IV
busulfan: Given IV
tacrolimus: Given IV or PO
methotrexate: Given IV
cytogenetic analysis: Correlative studies
flow cytometry: Correlative studies
pharmacological study: Correlative studies
pharmacogenomic studies: Correlative studies
peripheral blood stem cell transplantation: Undergo PBPC transplantation
allogeneic hematopoietic stem cell transplantation: Undergo allogeneic transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Non-relapse Mortality (NRM) (Patients With AML/MDS)</title>
          <description>Cumulative incidence rate with death as a competing risk, assessed at day 100.</description>
          <units>percent</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 3 years after enrollment</time_frame>
      <desc>Causes of death were recorded as adverse events. Other adverse events were not recorded in this study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Cyclophosphamide, Busulfan, Transplant)</title>
          <description>CONDITIONING REGIMEN: Patients receive cyclophosphamide IV on days -7 and -6 and busulfan IV over 3 hours on days -5 to -2.
TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplant on day 0.
POST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive tacrolimus IV or PO twice daily on days -1 to 200 with taper on day 56 and methotrexate on days 1, 3, 6, and 11.
cyclophosphamide: Given IV
busulfan: Given IV
tacrolimus: Given IV or PO
methotrexate: Given IV
cytogenetic analysis: Correlative studies
flow cytometry: Correlative studies
pharmacological study: Correlative studies
pharmacogenomic studies: Correlative studies
peripheral blood stem cell transplantation: Undergo PBPC transplantation
allogeneic hematopoietic stem cell transplantation: Undergo allogeneic transplantation</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Recurrent or progressive malignancy</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>graft-versus-host disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection associated with graft-versus-host disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>infection not associated with graft-versus-host disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Secondary malignancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>H. Joachim Deeg MD</name_or_title>
      <organization>FHCRC</organization>
      <phone>206 667 4409</phone>
      <email>jdeeg@fhcrc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

